CERS
Price
$1.39
Change
+$0.03 (+2.21%)
Updated
Jul 25 closing price
Capitalization
342.62M
10 days until earnings call
HAE
Price
$75.20
Change
+$0.94 (+1.27%)
Updated
Jul 25 closing price
Capitalization
4.33B
12 days until earnings call
Interact to see
Advertisement

CERS vs HAE

Header iconCERS vs HAE Comparison
Open Charts CERS vs HAEBanner chart's image
Cerus
Price$1.39
Change+$0.03 (+2.21%)
Volume$531.44K
Capitalization342.62M
Haemonetics
Price$75.20
Change+$0.94 (+1.27%)
Volume$315.96K
Capitalization4.33B
CERS vs HAE Comparison Chart in %
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HAE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. HAE commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and HAE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (CERS: $1.39 vs. HAE: $75.20)
Brand notoriety: CERS and HAE are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 46% vs. HAE: 57%
Market capitalization -- CERS: $342.62M vs. HAE: $4.33B
CERS [@Medical Specialties] is valued at $342.62M. HAE’s [@Medical Specialties] market capitalization is $4.33B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileHAE’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • HAE’s FA Score: 0 green, 5 red.
According to our system of comparison, both CERS and HAE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while HAE’s TA Score has 5 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • HAE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HAE is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical Specialties) experienced а +2.21% price change this week, while HAE (@Medical Specialties) price change was +3.65% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.01%. For the same industry, the average monthly price growth was +4.92%, and the average quarterly price growth was -2.24%.

Reported Earning Dates

CERS is expected to report earnings on Oct 30, 2025.

HAE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Medical Specialties (+3.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HAE($4.34B) has a higher market cap than CERS($343M). HAE YTD gains are higher at: -3.689 vs. CERS (-9.740). HAE has higher annual earnings (EBITDA): 264M vs. CERS (-26.34M). HAE has more cash in the bank: 194M vs. CERS (65.9M). CERS has less debt than HAE: CERS (96M) vs HAE (871M). HAE has higher revenues than CERS: HAE (1.27B) vs CERS (156M).
CERSHAECERS / HAE
Capitalization343M4.34B8%
EBITDA-26.34M264M-10%
Gain YTD-9.740-3.689264%
P/E RatioN/A34.47-
Revenue156M1.27B12%
Total Cash65.9M194M34%
Total Debt96M871M11%
FUNDAMENTALS RATINGS
CERS vs HAE: Fundamental Ratings
CERS
HAE
OUTLOOK RATING
1..100
2469
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9647
PRICE GROWTH RATING
1..100
6454
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (43) in the Medical Specialties industry is in the same range as HAE (72). This means that CERS’s stock grew similarly to HAE’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HAE (100). This means that CERS’s stock grew similarly to HAE’s over the last 12 months.

HAE's SMR Rating (47) in the Medical Specialties industry is somewhat better than the same rating for CERS (96). This means that HAE’s stock grew somewhat faster than CERS’s over the last 12 months.

HAE's Price Growth Rating (54) in the Medical Specialties industry is in the same range as CERS (64). This means that HAE’s stock grew similarly to CERS’s over the last 12 months.

HAE's P/E Growth Rating (92) in the Medical Specialties industry is in the same range as CERS (100). This means that HAE’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSHAE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
56%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
69%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 9 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HAE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ILIKF0.610.01
+0.83%
Ilika PLC.
SKSUY85.79N/A
N/A
Sekisui Chemical Co.
CSPHF0.62N/A
N/A
CSTONE PHARMACEUTICALS
APRAF0.24-0.01
-3.33%
Trailbreaker Resources Ltd.
NAUBF24.58-1.11
-4.32%
National Australia Bank Ltd. (Victoria, Australia)

HAE and

Correlation & Price change

A.I.dvisor indicates that over the last year, HAE has been loosely correlated with ATR. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if HAE jumps, then ATR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HAE
1D Price
Change %
HAE100%
+1.27%
ATR - HAE
41%
Loosely correlated
-0.51%
CNMD - HAE
39%
Loosely correlated
+2.80%
OM - HAE
39%
Loosely correlated
+5.22%
GH - HAE
39%
Loosely correlated
-2.35%
CERS - HAE
37%
Loosely correlated
+2.21%
More